Amylyx Pharmaceuticals, Inc. AMLX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s operating income?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported operating income of -$43.78M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s operating income changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s operating income decreased by 15.8% year-over-year, from -$37.8M to -$43.78M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s operating income?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s operating income has grown at a 16.7% compound annual growth rate (CAGR), from -$82.69M to -$153.29M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.